Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at Tractocile har vist sig lige så effektivt som beta- agonister til at udsætte truende for tidlig fødsel, og at resultaterne med Tractocile er bedre, fordi dette lægemiddel tåles bedre.
The Committee for Medicinal Products for Human Use (CHMP) concluded that Tractocile has shown an effectiveness in delaying pre-term birth that is the same as seen with beta-agonists, and that the better outcome with Tractocile was due to the medicine being better tolerated.